---
title: "Understanding the Market | LEPU BIO-B rose over 6% in the afternoon, with excellent Phase I clinical data for MRG006A in treating advanced liver cancer"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/289557893.md"
description: "LEPU BIO-B rose over 6% in the afternoon, and as of the time of writing, it is up 4.74%, priced at HKD 3.98, with a transaction volume of HKD 41.495 million. In terms of news, LEPU BIO disclosed excellent Phase I clinical trial data for MRG006A targeting advanced liver cancer patients after standard treatment failure at the 2026 ASCO. MRG006A enters the liver cancer field, which currently has no approved ADCs globally, representing a new pathway that has not been fully developed and has already preliminarily crossed the clinical validation threshold. This suggests it could become the next Chinese first-in-class ADC project with BD imagination space. Notably, LEPU BIO previously announced that its self-developed antibody-drug conjugate MRG007 targeting CDH17 has officially received acceptance for its new drug clinical trial application from the National Medical Products Administration's Drug Evaluation Center. This new clinical acceptance marks a critical milestone in its clinical development in the gastrointestinal tumor field, and it is expected to provide millions of domestic patients with advanced gastrointestinal tumors with new treatment options in the future"
datetime: "2026-06-12T06:57:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/289557893.md)
  - [en](https://longbridge.com/en/news/289557893.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/289557893.md)
---

# Understanding the Market | LEPU BIO-B rose over 6% in the afternoon, with excellent Phase I clinical data for MRG006A in treating advanced liver cancer

According to Zhitong Finance APP, LEPU BIO-B (02157) rose over 6% in the afternoon, and as of the time of writing, it is up 4.74%, priced at HKD 3.98, with a transaction volume of HKD 41.495 million.

In terms of news, LEPU BIO disclosed excellent Phase I clinical trial data for MRG006A targeting patients with advanced liver cancer after standard treatment failure at the 2026 ASCO. MRG006A enters a field of liver cancer where no ADC has been approved globally, representing a new pathway that has not been fully developed and has already preliminarily crossed the clinical validation threshold. This suggests that it may become the next China first-in-class ADC project with BD potential.

It is worth noting that LEPU BIO previously announced that its self-developed antibody-drug conjugate MRG007 targeting CDH17 has officially received acceptance for its new drug clinical trial application from the National Medical Products Administration's Drug Evaluation Center. This new clinical acceptance marks a critical milestone in its clinical development in the field of gastrointestinal tumors, and it is expected to bring new treatment options for millions of patients with advanced gastrointestinal tumors in China in the future

### Related Stocks

- [02157.HK](https://longbridge.com/en/quote/02157.HK.md)

## Related News & Research

- [Lepu Biopharma Signals 2025 Profit on Strong Oncology Sales and Licensing Gains](https://longbridge.com/en/news/278629108.md)
- [Shanghai Henlius says first US patient dosed in Phase 1 trial of ipilimumab biosimilar HLX13 for advanced liver cancer](https://longbridge.com/en/news/290813976.md)
- [The evolution of the ADC market – and what it means for commercial packaging](https://longbridge.com/en/news/290423990.md)
- [Elron subsidiary RDC targets M&A with up to $150 million Rafael financing over three years](https://longbridge.com/en/news/290676463.md)
- [ZAWYA: SEHA’s Tawam Hospital hosts “Best of ASCO 2026 UAE”](https://longbridge.com/en/news/291039623.md)